4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lowered its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 13.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 26,546 shares of the company’s stock after selling 3,989 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.06% of 4D Molecular Therapeutics worth $148,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in 4D Molecular Therapeutics in the 4th quarter valued at $48,000. PNC Financial Services Group Inc. grew its stake in 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after acquiring an additional 3,630 shares during the period. Daiwa Securities Group Inc. boosted its stake in 4D Molecular Therapeutics by 5,291.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after purchasing an additional 9,737 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in 4D Molecular Therapeutics during the 4th quarter worth $69,000. Finally, AlphaQuest LLC boosted its stake in 4D Molecular Therapeutics by 3,665.2% during the 4th quarter. AlphaQuest LLC now owns 14,835 shares of the company’s stock worth $83,000 after purchasing an additional 14,441 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Up 7.5%

Shares of FDMT opened at $3.44 on Friday. The stock has a 50 day moving average price of $3.30 and a 200 day moving average price of $5.10. The company has a market capitalization of $159.36 million, a price-to-earnings ratio of -1.21 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on FDMT shares. The Goldman Sachs Group reduced their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Weiss Ratings restated a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a report on Saturday, May 10th. Bank of America dropped their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Finally, Barclays dropped their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.